Nuo Therapeutics, Inc. (AURX) — Quarterly Report

Key Insights

• The filing shows a Q1 2026 10-Q for Nuo Therapeutics (AURX) with complex capital structure including multiple warrant classes (Capital Initial Warrants, Commitment Warrants, Sales Incentive Warrants) and a loan agreement with four lenders dated January 21, 2026, indicating recent financing activity and potential dilution concerns.
• The company has two primary product lines tracked separately: Aurix System and Private Label products, with distribution agreements and equipment assets (warehouse, production, medical equipment) suggesting ongoing manufacturing and commercial operations with revenue generation.
• Significant customer concentration risk is documented with Customer A representing material accounts receivable and revenue, creating vulnerability to customer loss and indicating dependence on a limited customer base for cash flow.
• The loan agreement structure with defined maximum thresholds and contingent warrant features suggests covenant restrictions and equity dilution mechanics tied to borrowing performance, which could impact shareholder value if borrowing increases.